Exelixis (NASDAQ: EXEL) saw its stock price plummet 10.77% in a 24-hour period on Monday following the release of its second-quarter 2025 financial results. The biotech company's performance painted a mixed picture, with an earnings beat overshadowed by a revenue miss and year-over-year decline in total revenues.
For Q2 2025, Exelixis reported total revenues of $568.3 million, falling short of the analyst consensus estimate of $574.5 million and marking a significant 10.8% decrease from $637.2 million in the same period last year. The decline was primarily due to the absence of a $150 million milestone payment recorded in Q2 2024. However, the company's adjusted earnings per share (EPS) of $0.75 surpassed expectations, beating the estimated $0.56 by 33.9%.
Despite the mixed results, Exelixis maintained its previously provided financial guidance for fiscal year 2025. The company continues to expect total revenues between $2.25 billion and $2.35 billion, with net product revenues projected at $2.05 billion to $2.15 billion. This maintained outlook, which some investors might view as conservative given the Q2 performance, appears to be contributing to the stock's significant decline. On a positive note, Exelixis reported encouraging progress in its pipeline, including positive topline results from the STELLAR-303 trial in colorectal cancer, which could pave the way for future growth opportunities. However, the market seems to be focusing on the near-term financial performance and the revenue shortfall in particular.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.